SecBot SecBot
6-K ·Filed Nov 12, 2026

GMAB

GENMAB A/S
NEUTRAL
Impact 2/10
Horizonimmediate Processed4d 15h ago SEC0001434265-26-000155
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine insider trade disclosure with no material impact. Monitor for any pattern of increased insider selling in future filings, but this single transaction is immaterial relative to Genmab's $33.7B market cap.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$51.74
T+0 close · Nov 12, 2026 · via day close
Latest settled
−0.72%
T+1 · $51.37
Vs SPY
−0.35%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $51.74entry
  2. T+1 · 4d ago −0.72%α −0.35% · $51.37
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Genmab filed a Form 6-K disclosing a sale of 1,071 shares by Executive Vice President and Chief Commercial Officer Bradley Bailey on November 11, 2026, at an average price of DKK 3,602.98 per share. This is a routine insider transaction disclosure with no material financial impact on the company.

Key Facts

  • Bradley Bailey, EVP and Chief Commercial Officer, sold 1,071 shares on November 11, 2026
  • Weighted average sale price was DKK 3,602.98 per share
  • Transaction took place on NASDAQ Copenhagen
  • Total proceeds approximately DKK 3.86 million (about $0.54 million at current exchange rates)
  • This is a routine disclosure under EU Market Abuse Regulation Article 19

Financial Impact

Sale of 1,071 shares at DKK 3,602.98 average price, total proceeds ~DKK 3.86M (approximately $0.54M)

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
80% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001434265-26-000155
Document: gmab_20261112x6kx3.htm0001434265-26-000155
Document: 0001434265-26-000155-index-headers.html0001434265-26-000155
Document: 0001434265-26-000155-index.html0001434265-26-000155
Document: 0001434265-26-000155.txt0001434265-26-000155
Earnings Context (Synthetic; results releases only)0001434265-26-000155

Track record

31 reports on GMAB

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +91.28% at T+60 after the Aug 6, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $52.12 Now $51.57 −1.06% settles Dec 15
  2. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
  3. Nov 12, 20264d ago 6-K Neutral 2/10 Viewing Entry $51.74 Now $51.57 −0.33% settles Dec 11
  4. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
  5. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
  6. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $53.87 Now $51.57 −4.27% settles Dec 10
  7. Nov 10, 20266d ago 144 Neutral 2/10 Entry $54.07 Now $51.57 −4.62% settles Dec 9
  8. Nov 5, 202611d ago 6-K Neutral 5/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
  9. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
  10. Oct 28, 202619d ago 6-K Bullish 6/10 Entry $57.29 Now $51.57 −9.98% settles Nov 25
Showing 10 of 31

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026